NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free GMAB Stock Alerts $29.69 -0.25 (-0.84%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$29.68▼$30.0150-Day Range$26.43▼$32.3952-Week Range$26.32▼$42.99Volume411,189 shsAverage Volume684,666 shsMarket Capitalization$19.62 billionP/E Ratio30.93Dividend YieldN/APrice Target$48.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside63.4% Upside$48.50 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 10 Articles This WeekInsider TradingN/AProj. Earnings Growth36.70%From $1.09 to $1.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector269th out of 947 stocksPharmaceutical Preparations Industry125th out of 435 stocks 3.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.50, Genmab A/S has a forecasted upside of 63.4% from its current price of $29.69.Amount of Analyst CoverageGenmab A/S has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently decreased by 19.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.5 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 6.29% of the stock of Genmab A/S is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 36.70% in the coming year, from $1.09 to $1.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 30.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 149.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 30.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 206.39.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesMarch 18, 2024 | nz.finance.yahoo.comThe 10 best dressed from the 2024 NAACP Image AwardsMarch 18, 2024 | globenewswire.comCompletion of share buy-back programMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 15, 2024 | ca.finance.yahoo.comGMAB Apr 2024 30.000 putMarch 15, 2024 | msn.comBiogen chief medical officer departs, joins Alto Neuroscience boardMarch 15, 2024 | markets.businessinsider.comGenmab To Repurchase Up To DKK 3.5 Bln Of SharesMarch 15, 2024 | globenewswire.comGenmab Announces Initiation of Share Buy-Back ProgramMarch 13, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 13, 2024 | globenewswire.comConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabMarch 13, 2024 | seekingalpha.comBeiGene gains as access to leukemia drug Brukinsa expandsMarch 11, 2024 | globenewswire.comTransactions in connection with share buy-back programMarch 4, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 4, 2024 | globenewswire.comTransactions in connection with share buy-back programMarch 1, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 1, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Genmab (GMAB)February 29, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 27, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 27, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseFebruary 27, 2024 | markets.businessinsider.comGenmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDAFebruary 27, 2024 | msn.comAbbVie/ Genmab win FDA priority review for lymphoma therapyFebruary 27, 2024 | businesswire.comU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaFebruary 26, 2024 | globenewswire.comU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaFebruary 26, 2024 | globenewswire.comTransactions in connection with share buy-back programFebruary 25, 2024 | msn.comBMO upgrades Genmab to outperform, cites diversification potentialFebruary 23, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 23, 2024 | globenewswire.comGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabSee More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$48.50 High Stock Price Target$50.00 Low Stock Price Target$46.00 Potential Upside/Downside+63.4%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.96 Trailing P/E Ratio30.93 Forward P/E Ratio27.24 P/E Growth1.42Net Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / Sales8.21 Cash Flow$1.21 per share Price / Cash Flow24.44 Book Value$6.95 per share Price / Book4.27Miscellaneous Outstanding Shares660,740,000Free Float650,570,000Market Cap$19.62 billion OptionableOptionable Beta0.98 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.73kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.7kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.95kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.43kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $115.95kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.1MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNBeiGeneNASDAQ:BGNETeva Pharmaceutical IndustriesNYSE:TEVAViatrisNASDAQ:VTRSView All CompetitorsInstitutional OwnershipWellington Management Group LLPSold 56,050 shares on 3/5/2024Ownership: 0.359%Goldman Sachs Group Inc.Sold 108,410 shares on 3/1/2024Ownership: 0.080%Royal London Asset Management Ltd.Sold 26,451 shares on 3/1/2024Ownership: 0.034%Price T Rowe Associates Inc. MDSold 11,227 shares on 2/16/2024Ownership: 0.029%Citadel Advisors LLCSold 100 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Genmab A/S was last updated on Friday, March 15, 2024 at 4:03 AM. Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has shown consistent growth in revenue and earnings over the past year, indicating a strong financial performance. The company has a robust pipeline of innovative biopharmaceutical products, including the latest versions with promising clinical trial results. Genmab A/S has a solid track record of successful collaborations with major pharmaceutical companies, enhancing its market position and revenue potential. Recent positive analyst recommendations and target price upgrades suggest a favorable outlook for Genmab A/S stock. The current stock price of Genmab A/S offers an attractive entry point for investors looking to capitalize on potential future growth. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Genmab A/S operates in a highly competitive and rapidly evolving biopharmaceutical industry, facing risks related to market competition and regulatory challenges. The company's stock price may be susceptible to volatility due to factors such as clinical trial outcomes, regulatory approvals, and market sentiment shifts. Genmab A/S's dependency on a few key products for a significant portion of its revenue poses concentration risk in its product portfolio. Fluctuations in global economic conditions and healthcare policies could impact Genmab A/S's financial performance and market valuation. Investors should carefully monitor any developments in the biopharmaceutical sector that could affect Genmab A/S's competitive position and growth prospects. GMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price target for 2024? 13 Wall Street research analysts have issued 12 month price targets for Genmab A/S's shares. Their GMAB share price targets range from $46.00 to $50.00. On average, they predict the company's share price to reach $48.50 in the next year. This suggests a possible upside of 63.4% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2024? Genmab A/S's stock was trading at $31.84 at the beginning of the year. Since then, GMAB stock has decreased by 6.8% and is now trading at $29.69. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 1,860,000 shares, a drop of 19.5% from the February 14th total of 2,310,000 shares. Based on an average daily trading volume, of 648,700 shares, the days-to-cover ratio is presently 2.9 days. Approximately 0.3% of the company's shares are sold short. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) posted its quarterly earnings results on Wednesday, February, 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. The company earned $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA).ActivePassive International Equity ETF (APIE). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (0.61%), Harding Loevner LP (0.50%), Wellington Management Group LLP (0.36%), First Trust Advisors LP (0.19%), Envestnet Asset Management Inc. (0.14%) and Stifel Financial Corp (0.10%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMAB) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.